Sugi Predict

Sugi Predict / Compounds / SCHEMBL2048168

SCHEMBL2048168

SCHEMBL2048168

OC[C@H]1OC(O)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 1/20 0.48
▸ PDPK1 O15530 2/20 0.46
▸ MTOR P42345 1/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ TACR2 P21452 1/20 0.46
▸ TSHR P16473 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ SSTR1 P30872 1/20 0.40
▸ SSTR2 P30874 1/20 0.40
▸ SSTR4 P31391 1/20 0.40
▸ SSTR3 P32745 1/20 0.40
▸ SSTR5 P35346 1/20 0.40
▸ SLC5A2 P31639 2/20 0.40
▸ LGALS8 O00214 1/20 0.39
▸ TNF P01375 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2783738 1.00 SLC6A2 (0.48) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL26048713 1.00 SLC6A2 (0.48) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL1118779 1.00 SLC6A2 (0.48) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL7155718 1.00 SLC6A2 (0.48) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL5985708 1.00 SLC6A2 (0.48) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL8156936 1.00 SLC6A2 (0.48) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL8755194 0.93 SLC6A2 (0.46) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL29974780 0.91 SLC6A2 (0.51) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL6552396 0.89 SLC6A2 (0.50) SLC6A2PDPK1MTORPDE4DTACR2
SCHEMBL6552387 0.89 SLC6A2 (0.50) SLC6A2PDPK1MTORPDE4DTACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107325070-B Preparation method of 2,3, 4-tri-O-benzyl-6-deoxy-D-glucopyranose-1, 5-lactone 吴赣药业（苏州）有限公司 2023-12-22 — — CN disclosed
CN-115916797-A Method for synthesizing macromolecules from carbohydrate derivative units in solution 斯特兰化学公司 2023-04-04 — — CN disclosed
EP-2627691-B1 DEGRADABLE POLYCARBONATES TEXAS A&M UNIV (US) 2020-11-25 — — EP disclosed
CN-103497199-B Dioxa-bicyclo[3.2.1]octane-2, 3, 4-triol derivatives PFIZER 2015-04-29 — — CN disclosed
EP-2627691-A1 DEGRADABLE POLYCARBONATES Texas A&M University (US) 2013-08-21 — — EP disclosed
WO-2012051448-A1 DEGRADABLE POLYCARBONATES TEXAS A&M UNIVERSITY (US) 2012-04-19 — — WO disclosed
US-7956041-B2 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide AJINOMOTO CO., INC. (JP) 2011-06-07 — — US disclosed
EP-2163555-A1 New pyrazole derivatives and diabetic medicine containing them Ajinomoto Co., Inc. (JP) 2010-03-17 — — EP disclosed
US-20100063124-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM AJINOMOTO CO., INC. (JP) 2010-03-11 — — US disclosed
US-7645787-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2010-01-12 — — US disclosed
US-6815428-B2 AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-09 — — US disclosed
US-20040006025-A1 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2004-01-08 — — US disclosed
EP-1338603-A1 NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2003-08-27 — — EP disclosed
EP-0971717-B1 CYTOTOXIC AMINO SUGAR AND RELATED SUGAR DERIVATIVES OF INDOLOPYRROLOCARBAZOLES BRISTOL MYERS SQUIBB CO (US) 2001-12-19 — — EP disclosed
EP-0971717-A4 CYTOTOXIC AMINO SUGAR AND RELATED SUGAR DERIVATIVES OF INDOLOPYRROLOCARBAZOLES BRISTOL MYERS SQUIBB CO (US) 2000-04-12 — — EP disclosed
EP-0971717-A1 CYTOTOXIC AMINO SUGAR AND RELATED SUGAR DERIVATIVES OF INDOLOPYRROLOCARBAZOLES Bristol-Myers Squibb Company (US) 2000-01-19 — — EP disclosed
US-5998595-A Azidohalogenobenzyl derivatives, sugar compounds and protection of hydroxy groups WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1999-12-07 — — US disclosed
WO-1998007433-A1 CYTOTOXIC AMINO SUGAR AND RELATED SUGAR DERIVATIVES OF INDOLOPYRROLOCARBAZOLES BRISTOL-MYERS SQUIBB COMPANY (US) 1998-02-26 — — WO disclosed
WO-1990004597-A1 TUMOR-INHIBITING SACCHARIDE CONJUGATES Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 1990-05-03 — — WO disclosed
US-4572907-A High caloric product for I.V. administration ABBOTT LABORATORIES (US) 1986-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006025-A1 Pyrazole derivatives and diabetic medicine containing them SLC5A2, SLC5A1, DPP4 SLC6A2 4156/4885PDPK1 301/4885MTOR 623/4885
US-20100063124-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM DPP4, SLC5A2, SLC5A1 SLC6A2 4502/4885PDPK1 367/4885MTOR 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.